NCT02752672|Completed
Loading search results
Sponsor study identifier
observational
27
1 country
1
Study Start
March 2016
Actual (reported)Primary Completion
November 2016
Actual (reported)Study Completion
November 2016
Actual (reported)Dithranol (known in the U.S.A. as anthralin and in Germany as cignolin) is one of the oldest and safest topical anti-psoriatic treatments. However, despite explorative investigations, the skin disease-clearing mechanisms of dithranol remain poorly understood (Painsi et al, JDDG 2015). The purpose of this study is to investigate the therapeutic mechanisms of dithranol in psoriasis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2016
Actual (reported)April 22, 2016
Actual (reported)April 27, 2016
Actual (reported)November 2016
Actual (reported)November 2016
Actual (reported)Protein and mRNA expression of pro- and contra-inflammatory factors in the skin and blood
day 0, 4, 14, 42
MicroRNA expression in skin and blood
day 0, 4, 14, 42
Size and density of lymph and blood vessels in the skin
day 0, 4, 14, 42
Angiogenic factors and their receptors in the skin
day 0, 4, 14, 42
Inflammatory infiltrate in the skin and alterations of the epidermis
day 0, 4, 14, 42
Microarray analysis of skin samples and subsequent targeted analysis of deregulated genes
day 0, 4, 14, 42
Psoriasis patients treated with dithranol
Non-Psoriasis patients undergoing surgery for skin lesions. Tumor-adjacent skin is collected for control purposes.
A total of maximal 15 psoriasis patients will be enrolled. Normal lesion-adjacent skin from 10 patients undergoing surgery for non-inflammatory conditions will serve as control.
Klinikum Klagenfurt am Woerthersee
Klagenfurt, Carinthia, 9020, Austria
Graier T, Golob-Schwarzl N, Weger W, Benezeder T, Painsi C, Salmhofer W, Wolf P. Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2? Front Med (Lausanne). 2021 Feb 10;8:624462. doi: 10.3389/fmed.2021.624462. eCollection 2021.
Benezeder T, Painsi C, Patra V, Dey S, Holcmann M, Lange-Asschenfeldt B, Sibilia M, Wolf P. Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis. Elife. 2020 Jun 2;9:e56991. doi: 10.7554/eLife.56991.
Skin Biopsies
27 participants (actual enrollment reported by the registry).
First Submitted
April 22, 2016
First Posted
April 27, 2016
Study Start
March 2016
Actual (reported)Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis
Contact the study team to confirm eligibility.
Primary Completion
November 2016
Actual (reported)Study Completion
November 2016
Actual (reported)Last Updated
October 30, 2017
Record last verified: 2017-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: